Pharmaceutical composition for treatment of cancer comprising compound for inhibiting cell-specific viral defence as active ingredient

摘要

The present invention relates to a pharmaceutical composition for cancer treatment comprising a compound for inhibiting a virus cell-specific defense mechanism as an active ingredient, and more specifically, a next-generation cancer cell through inhibition of APOBEC3G (Apolipoprotein B mRNA Editing Catalytic Polypeptide-like 3G) It relates to the treatment of cancer by improving the infection efficiency of a specific replicable retroviral vector (spRRV). The pharmaceutical composition for cancer treatment comprising the compound for inhibiting the virus cell-specific defense mechanism through the present invention as an active ingredient not only significantly increased virus infection efficiency through cell experiments, but also at the same time stable solubility, high metabolic safety, and pharmacokinetics It is expected to be able to dramatically improve the anti-cancer effect by significantly improving the infection efficiency of the next-generation cancer cell-specific replicable retrovirus vector (spRRV) for anti-cancer virotherapy.